Incannex Healthcare Inc (IXHL) - News Archive

In the fast-evolving landscape of biotech and pharmaceuticals, securing adequate funding is often the linchpin for advancing innovative therapies and sustaining growth. Recently, Incannex Healthcare, a company focused o...

FDA Approves Incannex Healthcare’s Phase 2 Clinical Trial for Psilocybin-Assisted Psychotherapy in Generalized Anxiety Disorder Patients In an exciting development for the field of psychiatric and psychedelic-assisted t...

Incannex Healthcare Advances Novel Therapeutics for Sleep Apnea and Rheumatoid Arthritis: Completion of Dosing in Bioavailability Trial and Launch of Phase 2 Study for IHL-675A Incannex Healthcare Inc., a clinical-stage...

Patient Dosing Commenced in RePOSA Phase 2/3 Clinical Trial to Evaluate the Efficacy of IHL-42X Drug in Patients with Obstructive Sleep ApneaObstructive Sleep Apnea (OSA) is a common sleep disorder that affects millions...

In a significant step forward in the battle against the opioid epidemic, Incannex Healthcare Inc., a leading cannabinoid and psychedelic medicine biotechnology company, has successfully completed a pre-IND (Investigatio...

In its latest quarterly activities update, Incannex Healthcare Inc., a clinical-stage pharmaceutical development company based in Melbourne, Australia, has shared its progress and achievements for the first quarter of 2...

Incannex Healthcare Inc., a prominent biotechnology company specializing in cannabinoid and psychedelic medicine, recently achieved a significant milestone in its pursuit of developing an effective solution for tobacco...

Rheumatoid arthritis (RA) is a chronic autoimmune disease characterized by inflammation and joint destruction, affecting millions of people globally. Current treatment options, such as nonsteroidal anti-inflammatory dru...

Incannex Healthcare Inc. (Nasdaq: IXHL), a pharmaceutical company specializing in developing medicinal cannabinoid pharmacotherapies and psychedelic medicine therapies, has recently received approval from an independent...